Researchers at the University of California, Davis have developed an approach to combat Feline Infectious Peritonitis (FIP) through an in vitro-transcribed (IVT) RNA vaccine targeting the FCoV nucleocapsid (N) protein antigen.

Please view this family of technologies HERE

Researchers at the University of California, Davis, have developed a monoclonal antibody for treating and diagnosing T cell lymphoma in dogs as well as monoclonal antibodies targeting c-KIT for treating and diagnosing mast cell tumors in dogs.

Researchers at the University of California, Davis have developed monoclonal antibodies engineered for the treatment and detection of autoimmune disorders and cancers in dogs.

Researchers at the University of California, Davis have developed a biologic dressing derived from fish skin to enhance wound healing.

Researchers at the University of California, Davis, have developed a 3D-printed implant for dogs and cats for treating TMJ ankylosis. The device can accommodate any sized animal and is produced with biocompatible materials with high stress/strain resistance.

Researchers at the University of California, Davis have developed a biologic treatment for mitigating pain and treating acute urinary tract infections (UTIs) in canines.

Researchers at the University of California, Davis have developed monoclonal antibodies with multiple applications relevant to canine PD-1 and PD-L1.

Researchers at the University of California, Davis have developed a program based on machine learning algorithms to aid in diagnosing hypoadrenocorticism.

Researchers at the University of California, Davis have developed a deep learning-based diagnostic tool that accurately detects left atrial enlargement in canine thoracic radiographs to aid early diagnosis of mitral valve disease.

Researchers at the University of California, Davis, have developed a diagnostic method to identify dogs that are at risk for chondrodystrophy and/or intervertebral disc disease.

Researchers at the University of California, Davis have discovered a new signal pathway involved in depression. This could be a potential target of pharmacological treatment of central nervous system disease and specially depression in man and companion animals. The technology could be best practiced with soluble epoxide hydrolase inhibitors, which have high oral bioavailability, good pharmacokinetics, picomolar potency, low toxicity and CNS activity.

Researchers at the University of California, Irvine have developed a novel high resolution imaging technique, referred to as Photo-Magnetic Imaging (PMI), that combines the abilities of optical and magnetic resonance (MR) imaging systems. Images are created with PMI by heating tissue with a light (e.g. laser) and measuring the resulting temperature change with MR Thermometry. This change in temperature can then be related to a tissue’s absorption, scattering, and metabolic properties. PMI addresses the limitations of current optical imaging techniques by providing a repeatable, non-contact, high resolution optical image with increased quantitative accuracy. This technique can be used for a wide-range of applications including but not limited to imaging of small animals for research purposes. This technique may also be used in imaging the tissue and organs of a patient.